Rallybio Corporation
RLYB
Rallybio Corporation, a clinical-stage biotechnology company, engages in discovering, developing, manufacturing, and delivering therapies that enhance the lives of patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that is in Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT). Tā¦ read more
Healthcare
Biotechnology
5 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$15.95
Price+0.13%
$0.02
1Y
Price
Market Cap
$84.645m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-2231.1%
EBITDA Margin-3904.7%
Net Profit Margin-3763.2%
Free Cash Flow Margin-2231.1%
EBITDA Margin-3904.7%
Net Profit Margin-3763.2%
Free Cash Flow MarginRevenue
$858k
-
1y CAGR+11.6%
3y CAGR+8.7%
5y CAGREarnings
-$7.817m
+12.9%
1y CAGR+40.0%
3y CAGR+27.0%
5y CAGREPS
-$1.49
+6.3%
1y CAGR+39.7%
3y CAGR+32.8%
5y CAGRBook Value
$50.277m
$54.472m
Assets$4.195m
Liabilities$154k
DebtDebt to Assets
0.3%
-
Debt to EBITDAFree Cash Flow
-$27.586m
+7.5%
1y CAGR+21.7%
3y CAGR+15.0%
5y CAGRNo items found.
Press Releases
Statements and updates from the company